EANS-Adhoc: Oxygen Biotherapeutics TBI Study To Be Offered to Injured Israel-based Soldiers

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Study/Biotechnology

08.09.2010

DURHAM, NC, September 7, 2010 — Oxygen Biotherapeutics, Inc. (NASDAQ
and SIX Swiss Exchange: OXBT), a development stage biomedical company
focused on developing oxygen-rich intravenous and topical products,
today announced that Israeli soldiers who suffer severe traumatic
brain injury (TBI) can be enrolled in the company´s Phase II-b
STOP-TBI trials at clinical sites in Israel. In view of this
development, the company announced that it seeks to amend the
existing study protocol to broaden the qualified patient enrollment
population to include moderate/mild TBI patients. The company
expects to reconvene enrollment in its second cohort after the
required regulatory adjustments have been approved. The result of
these two actions should increase the patient population that
qualifies for enrollment in the study.

"Today, traumatic brain injury is one of the most common impairments
faced by military personnel all over the world. Land mines,
rocket-propelled grenades and improvised explosive devices are now
the most common tools of war. When they strike, body armor and
helmets may protect, but what is not as easily recognizable is the
damage these weapons are doing to service members´ brains. Sometimes
it is an obvious injury; other times it is mild to moderate.
Therefore, we are considering modifying our study protocol to include
moderate/mild TBI cases. As a company, we believe it is our duty to
help these men and women who otherwise have little to no solution
when afflicted with a brain injury. We are pleased that the Israeli
Medical Corps will allow soldiers to participate," said Chris Stern,
Chairman and Chief Executive Officer of Oxygen Biotherapeutics.

Currently, Oxygen Biotherapeutics has a Phase II-b clinical study
underway to determine the safety and efficacy of using Oxycyte
intravenously to treat severe TBI patients. These studies are being
conducted at clinical sites in Switzerland and Israel with plans to
expand into India. The company expects to allocate a substantial
portion of its financial and business resources over the next few
years to testing Oxycyte and advancing this product to regulatory
approval for use in one or more medical applications.

end of ad-hoc-announcement ==========================================
====================================== Oxycyte oxygen carrier is a
perfluorocarbon emulsified with water and a surfactant, which is
provided to the patient intravenously. The physical properties of
Oxycyte enable it to gather oxygen from the lungs and transport the
oxygen through the body releasing it along the way. Increased
oxygenation is vital for the recovery of TBI patients. TBI is a
non-degenerative, non-congenital insult to the brain from an external
mechanical force, possibly leading to permanent or temporary
impairment of cognitive, physical, and psychosocial functions, with
an associated diminished or altered state of consciousness.

About Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is
developing medical and cosmetic products that efficiently deliver
oxygen to tissues in the body. The Company has developed a
proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and
liquid ventilation product called Oxycyte® that is being formulated
for both intravenous and topical delivery for conditions including
but not limited to traumatic brain injury, decompression sickness and
topical wounds. This same PFC is included in the Company’s full line
of personal skin care products. More information is available at
www.oxybiomed.com.

Caution Regarding Forward-Looking Statements This news release
contains certain forward-looking statements by the company that
involve risks and uncertainties and reflect the company's judgment as
of the date of this release. These statements include the expansion
of development of the Oxycyte and DERMACYTE product lines and the
timing of the introduction of those new products. The forward-looking
statements are subject to a number of risks and uncertainties
including matters beyond the company's control that could lead to
delays in new product introductions and customer acceptance of these
new products, and other risks and uncertainties as described in our
filings with the Securities and Exchange Commission, including in the
current reports on Form 10-Q and Form-10K. The company disclaims any
intent or obligation to update these forward-looking statements
beyond the date of this release. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Oxygen Biotherapeutics Inc.
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Ellen Corliss

Vice President, Corporate Communications

& Investor Relations

Oxygen Biotherapeutics, Inc

2530 Meridian Pkwy, 3rd floor

Durham, NC 27713

Direct Telephone: +1 919 806 4405

Direct Fax: +1 919 806 4417

Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN: US69207P2092
WKN: 10728277
Index: SSIRT
Börsen: New York / Nasdaq
SIX Swiss Exchange / Main Standard